Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%

Caris Life Sciences, Inc.

2025-FY EPS reported -$3.22 revenue$812,033,000

Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.
Full-year 2025 revenue ~$800M (+94% YoY); Pharma R&D services ~$45M.
Q4 clinical therapy selection cases ~52,700 (+20%); full-year ~199,300 (+22%).
Cash, equivalents and marketable securities ~$802M as of Dec 31, 2025, up ~$43M from Sep 30, 2025.
Company presenting at 44th J.P. Morgan Healthcare Conference today; complete earnings call expected in late Feb 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.